Pfizer completes acquisition of seagen

New york--(business wire)--pfizer inc. (nyse: pfe) today announced the successful completion of its acquisition of seagen inc. (nasdaq: sgen), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. pfizer completed its acquisition of all outstanding common stock of seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion. “cancer remains a leading cause of death, and one in three people in the u.s. will rec.
SGEN Ratings Summary
SGEN Quant Ranking